Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NQO2 | P16083 | 3/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.39 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.36 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.33 |
| ▸ | TXNRD3 | Q86VQ6 | 1/20 | 0.33 |
| ▸ | TXNRD2 | Q9NNW7 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 3/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
| ▸ | GABRP | O00591 | 1/20 | 0.32 |
| ▸ | GABRD | O14764 | 1/20 | 0.32 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.32 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.32 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL62556 | 0.83 | ITGB2 (0.36) | TSHRLMNAGAAALDH1A1 | |
| SCHEMBL161183 | 0.78 | ABCG2 (0.39) | NQO2CYP19A1ABCG2TXNRD1TXNRD3 | |
| SCHEMBL3404505 | 0.77 | ABCG2 (0.37) | NQO2CYP19A1ABCG2TXNRD1TXNRD3 | |
| SCHEMBL9394553 | 0.75 | ABCG2 (0.36) | NQO2CYP19A1ABCG2TXNRD1TXNRD3 | |
| SCHEMBL3351629 | 0.75 | AOC3 (0.39) | NQO2ABCG2TXNRD1TXNRD3TXNRD2 | |
| SCHEMBL6904035 | 0.75 | ABCG2 (0.36) | NQO2ABCG2TXNRD1TXNRD3TXNRD2 | |
| SCHEMBL63619 | 0.75 | AOC3 (0.35) | NQO2CYP19A1ABCG2TXNRD1TXNRD3 | |
| SCHEMBL5907509 | 0.75 | NQO2 (0.37) | NQO2CYP19A1ABCG2CYP3A4CYP2D6 | |
| SCHEMBL8638641 | 0.74 | MAPT (0.39) | NQO2CYP19A1TSHRLMNAGAA | |
| SCHEMBL4060952 | 0.71 | TAAR1 (0.33) | ABCG2TXNRD1TXNRD3TXNRD2AOC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9802936-B2 | Ketone ligands for modulating the expression of exogenous genes via an ecdysone receptor complex | INTREXON CORPORATION (US) | 2017-10-31 | — | — | US | claimed |
| EP-2392561-B1 | Alpha-acylaminoketone ligands for modulating the expression of exogenous genes via an ecdysone receptor complex | INTREXON CORP (US) | 2016-09-14 | — | — | EP | claimed |
| EP-1534658-B1 | KETONE LIGANDS FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES VIA AN ECDYSONE RECEPTOR COMPLEX | INTREXON CORP (US) | 2016-09-07 | — | — | EP | claimed |
| US-8129355-B2 | Nuclear receptor-based inducible gene expression system; modulating the expression of a gene in a host cell by introducing into the host cell a gene expression modulation system and activating that system using 5-ethyl-2,3-dihydro-benzo[1,4]dioxine-6-carboxylic acid (1-benzoyl-cyclopentyl)-amide | INTREXON CORPORATION (US) | 2012-03-06 | — | — | US | claimed |
| EP-2392561-A1 | Alpha-acylaminoketone ligands for modulating the expression of exogenous genes via an ecdysone receptor complex | Intrexon Corporation (US) | 2011-12-07 | — | — | EP | claimed |
| US-20090111183-A1 | Ketone Ligands for Modulating the Expression of Exogenous Genes Via An Ecdysone Receptor Complex | RHEOGENE, INC. | 2009-04-30 | — | — | US | claimed |
| US-20080125465-A1 | Ketone ligands for modulating the expression of exogenous genes via an ecdysone receptor complex | INTREXON CORPORATION (US) | 2008-05-29 | — | — | US | claimed |
| US-7375093-B2 | Ketone ligands for modulating the expression of exogenous genes via an ecdysone receptor complex | INTREXON CORPORATION (US) | 2008-05-20 | — | — | US | claimed |
| EP-1534658-A4 | KETONE LIGANDS FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES VIA AN ECDYSONE RECEPTOR COMPLEX | RHEOGENE INC (US) | 2006-10-04 | — | — | EP | claimed |
| EP-1534658-A2 | KETONE LIGANDS FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES VIA AN ECDYSONE RECEPTOR COMPLEX | RheoGene, Inc. (US) | 2005-06-01 | — | — | EP | claimed |
| US-20040049037-A1 | Ketone ligands for modulating the expression of exogenous genes via an ecdysone receptor complex | RHEOGENE, INC. | 2004-03-11 | — | — | US | claimed |
| WO-2004005478-A2 | KETONE LIGANDS FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES VIA AN ECDYSONE RECEPTOR COMPLEX | RHEOGENE, INC (US) | 2004-01-15 | — | — | WO | claimed |
| US-9802936-B2 | Ketone ligands for modulating the expression of exogenous genes via an ecdysone receptor complex | INTREXON CORPORATION (US) | 2017-10-31 | — | — | US | disclosed |
| EP-2392561-B1 | Alpha-acylaminoketone ligands for modulating the expression of exogenous genes via an ecdysone receptor complex | INTREXON CORP (US) | 2016-09-14 | — | — | EP | disclosed |
| EP-1534658-B1 | KETONE LIGANDS FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES VIA AN ECDYSONE RECEPTOR COMPLEX | INTREXON CORP (US) | 2016-09-07 | — | — | EP | disclosed |
| US-8129355-B2 | Nuclear receptor-based inducible gene expression system; modulating the expression of a gene in a host cell by introducing into the host cell a gene expression modulation system and activating that system using 5-ethyl-2,3-dihydro-benzo[1,4]dioxine-6-carboxylic acid (1-benzoyl-cyclopentyl)-amide | INTREXON CORPORATION (US) | 2012-03-06 | — | — | US | disclosed |
| WO-2004005478-A2 | KETONE LIGANDS FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES VIA AN ECDYSONE RECEPTOR COMPLEX | RHEOGENE, INC (US) | 2004-01-15 | — | — | WO | disclosed |
| US-5594006-A | SUCH AS COLLEGENASE, STROMELYSIN; ANTICANCER AGENTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1997-01-14 | — | — | US | disclosed |
| EP-0641323-A1 | CARBOSTYRIL DERIVATIVES AS MATRIX METALLOPROTEINASES INHIBITORS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1995-03-08 | — | — | EP | disclosed |
| WO-1994021612-A1 | CARBOSTYRIL DERIVATIVES AS MATRIX METALLOPROTEINASES INHIBITORS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1994-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090111183-A1 | Ketone Ligands for Modulating the Expression of Exogenous Genes Via An Ecdysone Receptor Complex | ESRRB, ESRRA, KDELR1 | NQO2 3937/4885CYP19A1 834/4885ABCG2 4864/4885 |
| US-20040049037-A1 | Ketone ligands for modulating the expression of exogenous genes via an ecdysone receptor complex | ESRRB, ESRRA, KDELR1 | NQO2 3937/4885CYP19A1 834/4885ABCG2 4864/4885 |
| US-20080125465-A1 | Ketone ligands for modulating the expression of exogenous genes via an ecdysone receptor complex | ESRRB, ESRRA, KDELR1 | NQO2 3937/4885CYP19A1 834/4885ABCG2 4864/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.